2 withdrawn. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Tuberous Sclerosis: new trials by email Literature Review of Tuberous Sclerosis trials Research Report on Tuberous Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Everolimus in Patients With Tuberous Sclerosis Complex Everolimus, Placebo - Facial Angiofibromas | Phase 2 / Phase 3 | Withdrawn | Hospices Civils de Lyon | 2020-12-01 | 2021-05-03 | |
| A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa BEZ235 - Malignant PEComa (Perivascular Epithelioid Cell Tumors) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2012-09-01 | 2013-08-02 |
Angiomyolipoma (1) · Perivascular Epithelioid Cell Neoplasms (1)
Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hamartoma (2) · Heredodegenerative Disorders, Nervous System (2) · Malformations of Cortical Development (2) · Malformations of Cortical Development, Group I (2) · Neoplasms (2) · Neoplasms, Multiple Primary (2) · Neoplastic Syndromes, Hereditary (2) · Nervous System Diseases (2) · Nervous System Malformations (2) · Neurocutaneous Syndromes (2) · Neurodegenerative Diseases (2) · Neoplasms by Histologic Type (1)
Everolimus (1) · dactolisib (1)
Hospices Civils de Lyon (1) · Novartis Pharmaceuticals (1)
France (1) · Spain (1)
2018 (1)